《大行》大和上調信達生物(01810.HK)目標價至95元 重申「買入」評級
大和發表報告表示,重申對信達生物(01810.HK)「買入」評級,目標價由58元上調至95元,此按現金流折現率作估值,主要基於根據美國臨床腫瘤醫學會年會,納入IBI363藥物的價值,現預測其於2028年和2029年在中國及全球上市,2035年風險調整後的高峰銷售額約為40億元人民幣和22億美元。此外,中國國家藥品監督管理局亦已批准馬杜單抗,該行亦上調成功概率假設至100%。
該行又指,公司完成5,500萬股配售,募集淨額約42.7億元,擁有額外現金和全球研發策略的靈活性。該行認為,鑑於IBI363的研發進展以及其他早期下一代免疫腫瘤和抗體藥物偶聯療法的資產,公司正開啟全球創新藥的新時代。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.